$58.02
+0.04 (+0.07%)
Open$57.98
Previous Close$57.98
Day High$58.02
Day Low$57.98
52W High$58.02
52W Low$15.82
Volume—
Avg Volume2.25M
Market Cap1.68B
P/E Ratio—
EPS$-2.51
SectorBiotechnology
Analyst Ratings
Hold
17 analysts
Price Target
-54.6% upside
Current
$58.02
$58.02
Target
$26.34
$26.34
$18.77
$26.34 avg
$31.12
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 545.80M | 533.51M | 481.00M |
| Net Income | 29.97M | 31.31M | 23.12M |
| Profit Margin | 5.5% | 5.9% | 4.8% |
| EBITDA | 42.09M | 36.52M | 35.99M |
| Free Cash Flow | 24.22M | 23.20M | 21.80M |
| Rev Growth | +0.6% | -0.7% | +10.6% |
| Debt/Equity | 0.27 | 0.34 | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |